TG Therapeutics, Inc. (TGTX)

Market Cap	4.62B
Revenue (ttm)	264.79M
Net Income (ttm)	-14.36M
Shares Out	143.52M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	48.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,544,897
Open	30.50
Previous Close	30.95
Day's Range	30.50 - 32.63
52-Week Range	12.84 - 36.84
Beta	2.22
Analysts	Strong Buy
Price Target	40.67 (+26.3%)
Earnings Date	Nov 4, 2024

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is an increase of 26.30% from the latest price.

Price Target

$40.67

(26.30% upside)

Analyst Consensus: Strong Buy